Shilpa Medicare Beheer
Beheer criteriumcontroles 4/4
De CEO Shilpa Medicare is Vishnukanth Bhutada, benoemd in Aug2022, heeft een ambtstermijn van 2.25 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 35.00M, bestaande uit 100% salaris en 0% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 8.87% van de aandelen van het bedrijf, ter waarde ₹ 6.88B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 3.2 jaar.
Belangrijke informatie
Vishnukanth Bhutada
Algemeen directeur
₹35.0m
Totale compensatie
| Percentage CEO-salaris | 100.0% |
| Dienstverband CEO | 2.3yrs |
| Eigendom CEO | 8.9% |
| Management gemiddelde ambtstermijn | 2.5yrs |
| Gemiddelde ambtstermijn bestuur | 3.2yrs |
Recente managementupdates
Recent updates
What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You
Sep 12
Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues
Jul 05What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You
Apr 12Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up
Feb 21Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt
Jan 02These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively
Jul 17Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt
Mar 17Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)
Sep 22Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Sep 07Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Aug 14Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load
Jan 27Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why
Sep 21Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Jun 17If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late
May 31Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Mar 07Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year
Feb 20Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Jan 26
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹611m |
| Jun 30 2024 | n/a | n/a | ₹448m |
| Mar 31 2024 | ₹35m | ₹35m | ₹319m |
| Dec 31 2023 | n/a | n/a | -₹7m |
| Sep 30 2023 | n/a | n/a | -₹119m |
| Jun 30 2023 | n/a | n/a | -₹321m |
| Mar 31 2023 | ₹35m | ₹35m | -₹325m |
| Dec 31 2022 | n/a | n/a | ₹51m |
| Sep 30 2022 | n/a | n/a | ₹213m |
| Jun 30 2022 | n/a | n/a | ₹599m |
| Mar 31 2022 | ₹97m | ₹16m | ₹607m |
| Dec 31 2021 | n/a | n/a | ₹395m |
| Sep 30 2021 | n/a | n/a | ₹376m |
| Jun 30 2021 | n/a | n/a | ₹631m |
| Mar 31 2021 | ₹97m | ₹16m | ₹1b |
| Dec 31 2020 | n/a | n/a | ₹2b |
| Sep 30 2020 | n/a | n/a | ₹2b |
| Jun 30 2020 | n/a | n/a | ₹2b |
| Mar 31 2020 | ₹99m | ₹10m | ₹2b |
| Dec 31 2019 | n/a | n/a | ₹1b |
| Sep 30 2019 | n/a | n/a | ₹1b |
| Jun 30 2019 | n/a | n/a | ₹944m |
| Mar 31 2019 | ₹75m | ₹10m | ₹1b |
| Dec 31 2018 | n/a | n/a | ₹1b |
| Sep 30 2018 | n/a | n/a | ₹1b |
| Jun 30 2018 | n/a | n/a | ₹1b |
| Mar 31 2018 | ₹81m | ₹16m | ₹1b |
Compensatie versus markt: De totale vergoeding ($USD 414.61K ) Vishnukanth } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 355.62K ).
Compensatie versus inkomsten: De vergoeding van Vishnukanth is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Vishnukanth Bhutada (62 yo)
2.3yrs
Tenure
₹35,000,000
Compensatie
Mr. Vishnukanth Chaturbhuj Bhutada, B. Pharm. serves as the Managing Director of Shilpa Medicare Limited since August 11, 2022 . Mr. Bhutada joined Shilpa Medicare Limited in November 1987.He serves as th...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Director | 2.3yrs | ₹35.00m | 8.87% ₹ 6.9b | |
| Chief Financial Officer | 3.5yrs | ₹14.73m | 0.0023% ₹ 1.8m | |
| VP of Projects & Operations and Whole-Time Director | no data | ₹16.26m | 0.032% ₹ 25.1m | |
| Company Secretary & Compliance Officer | 2.5yrs | ₹4.51m | geen gegevens | |
| Chief Operating Officer of Formulations | no data | ₹26.95m | geen gegevens | |
| President of Global R&D | no data | ₹11.50m | geen gegevens | |
| Senior Vice President – Domestic Formulations and Biologics | no data | ₹3.90m | geen gegevens | |
| Senior Vice President of Formulation | no data | ₹12.50m | geen gegevens | |
| Executive Vice President – Formulations for Small Molecules | no data | ₹2.50m | geen gegevens | |
| Vice President | no data | ₹12.77m | geen gegevens | |
| Senior Vice President of Technical | no data | ₹6.06m | geen gegevens | |
| Chief Human Resource Officer | no data | geen gegevens | geen gegevens |
2.5yrs
Gemiddelde duur
53.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SHILPAMED wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Director | 37yrs | ₹35.00m | 8.87% ₹ 6.9b | |
| VP of Projects & Operations and Whole-Time Director | 5.1yrs | ₹16.26m | 0.032% ₹ 25.1m | |
| Non-Executive Independent Director | 3.2yrs | ₹3.00m | geen gegevens | |
| Non-Executive Independent Director | 2.3yrs | ₹3.00m | geen gegevens | |
| Non-Executive Independent Director | 3.2yrs | ₹4.00m | 0.0092% ₹ 7.1m | |
| Non-Executive Chairman | 36.7yrs | ₹350.00k | 3.3% ₹ 2.6b | |
| Independent Women Director | 2.3yrs | ₹1.80m | geen gegevens |
3.2yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SHILPAMED wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).